Journal of Clinical Oncology

Article	Citations
Radiation therapy and associated cardiovascular outcomes in patients with Hodgkin’s lymphoma.	1285
A randomized trial of topical cannabis balms for the treatment of aromatase inhibitor–associated musculoskeletal syndrome (AIMSS).	902
Ubiquitin ligase subunit FBXO9 inhibits V-ATPase assembly and lung cancer metastasis.	873
Clinical outcomes and prognostic factors in epithelial-myoepithelial carcinoma (EMC) of the breast.	630
STELLAR-305: A randomized phase 2/3 study of zanzalintinib plus pembrolizumab versus pembrolizumab alone in patients with previously untreated PD-L1 positive recurrent/metastatic head and neck squamou	628
Circulating tumor DNA analysis in patients with BRAF-mutated metastatic cutaneous melanoma treated with BRAF and MEK inhibitors: Analysis of the OPTIMEL study.	543
Patient characteristics, treatment patterns and early trends of lutetium Lu 177 vipivotide tetraxetan (177Lu-PSMA-617) use by US urologists and oncologists.	536
Health state utility assessment for low-grade glioma.	513
Association of a clinical model based on skeletal muscle radiation attenuation with efficacy for patients with gastric cancer treated with chemotherapy plus PD-1 antibodies: A single-center retrospect	492
Phase II study of the combination of lenvatinib (L) and eribulin (E) in advanced solid tumors.	482
Prognostic indicators of recurrence after surgical resection in non-pancreatic gastrointestinal neuroendocrine tumors.	482
5-hydroxymethylcytosine in cell-free DNA as liquid biomarker for immune checkpoint inhibitor therapy in non–small cell lung cancer.	480
Portal vein thrombosis in gastrointestinal cancers: Insights into prevalence and prognosis—A nationwide inpatient analysis 2018-2020.	477
Percutaneous cryoablation of breast cancer metastases: Analysis of long-term single center experience, efficacy and outcomes.	433
Longitudinal changes in triceps skinfold thickness and serum albumin during chemotherapy in patients with pancreatic cancer: Gender-based prognostic insights—A prospective cohort study.	410
FOLFOX as a therapeutic option in patients with hepatic failure due to liver metastasis of gastrointestinal (GI) system malignancies: A case series.	381
Genomic and immune landscape of biliary tract cancers with ARID1A, PBRM1, and BAP1 alterations.	380
Improved survival from early combined radiotherapy: A phase II clinical study and underlying mechanisms of delaying EGFR-TKI acquired resistance in patients with advanced lung cancer.	365
Effect of cerebral dopamine metabolism genetic polymorphism on patient-reported quality-of-life (QOL): An analysis of the E3805 CHAARTED trial.	363
DNA damaging therapies in patients (pts) with prostate cancer (PC) and pathogenic alterations in homologous recombination repair (HRR) genes.	361
Subgroup analysis in RE-MIND2, an observational, retrospective cohort study of tafasitamab plus lenalidomide versus systemic therapies in patients with relapsed/refractory diffuse large B-cell lymphom	338
Feasibility of a child life specialist program for oncology patients with minor children at home: Qualitative analysis.	330
Phase II study of nivolumab (nivo) with relatlimab (rela) in patients (pts) with first-line advanced melanoma: Early on-treatment major pathologic response on biopsy.	328
Systematic Review on Electronic Health Interventions for Patients With Breast Cancer: Revisiting the Methodology	325
A platform for high-resolution immune liquid biopsy analysis to predict response in patients with renal cell carcinoma treated with nivolumab or cabozantinib: Preliminary data from I-RENE trial (Meet-	317

A phase Ib/II study (IMMCO-1) of atezolizumab plus tivozanib in immunologically cold pancreatic, gallbladder, and biliary cancers.	315
Comprehensive genomic profiling (CGP)-informed personalized molecular residual disease (MRD) detection: An exploratory analysis from the PREDATOR study of metastatic colorectal cancer (mCRC) patients	310
A phase 1/2 study of REGN4336, a PSMAxCD3 bispecific antibody, alone and in combination with cemiplimab in patients with metastatic castration-resistant prostate cancer.	307
Randomized phase II study to assess the efficacy and tolerability of sunitinib by dose administration regimen in anti-angiogenic naïve patients with metastatic renal cell carcinoma (mRCC): Final analy	304
Single cell phenotyping of PDL1 and HLA1 on circulating tumor cells (CTC) in clear cell renal cell carcinoma (ccRCC) on systemic treatment with immunotherapy (IO) and vascular endothelial growth facto	303
NETOS: A personalized approach of neoadjuvant therapy, including INCB099280 monotherapy and bladder preservation, for muscle-invasive urothelial bladder carcinoma (MIBC) with ctDNA monitoring.	300
Preference-weighted quality of life: Findings from the Selenium and Vitamin E Cancer Prevention Trial (SELECT).	295
A phase Ⅱ, non-randomized, prospective trial of biweekly nab-paclitaxel in combination with ramucirumab for patients with previously treated advanced gastric or gastroesophageal junction cancer: B-RAX	288
Exploratory analysis of biomarkers of response to durvalumab in advanced HER2-negative oesophago-gastric adenocarcinoma within a phase 2 clinical trial.	285
Progression pattern and post-progression survival following atezolizumab and bevacizumab treatment in advanced hepatocellular carcinoma.	270
Liver steatosis and fibrosis as independent prognostic factors affecting survival in colorectal cancer with liver metastases.	268
Clinical characteristics and outcomes of patients with metastatic colitis-associated cancer treated with EGFR inhibitors.	267
Ground-glass opacity showed response to immunotherapy in cancer patients.	261
The role of exosomal LINC00853 in gastric cancer progression.	258
Consistency and heterogeneity of microsatellite instability (MSI) status in paired biopsy and surgical specimens of colorectal cancer: A necessity for MSI reassessment after treatment?	257
The power of glycobiology: Precision of polyp detection using glycoproteomic biomarkers.	251
Prognostic impact of local recurrence and timing of palliative radiotherapy in patients with unresectable recurrent rectal cancer.	250
A phase II trial of TAS-102 in patients with colorectal cancer with ctDNA-defined minimal residual disease post-adjuvant therapy: Results from the MD Anderson INTERCEPT Program.	247
Assessing disparities in pancreatic cancer outcomes in African Americans.	242
Immune-related adverse events in patients with gastrointestinal cancer undergoing pembrolizumab monotherapy: A systematic review of clinical trials.	241
Characterizing the rare abdominal neoplasms of peritoneum, retroperitoneum, and overlapping sites of peritoneum and retroperitoneum: A review of NCDB database.	237
Genetic testing of Japanese patients with serrated polyposis syndrome: A multicentric study.	237
A combined phase I/II study of a novel bicycle tumor-targeted immune cell agonist BT7480 in patients with nectin-4 associated advanced malignancies.	235
Assessing the impact of hypercalcemia of malignancy on clinical outcomes in cancer patients admitted with acute pancreatitis.	233
Association of circulating T lymphocytes and their functional states with pathologic complete response (pCR) in breast cancer (BC). A prospective Italian study.	230
Underutilization of standard of care (SOC) treatment intensification in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) by specialty.	230
Implementation of a virtual tumor board through VA National TeleOncology service.	227
Efficacy of alpelisib (ALP) + fulvestrant (FUL) with rational use of metformin (MET) in patients with HR+/HER2- advanced breast cancer (ABC).	225
Using an AI trial screening tool to assess language as a barrier for enrollment of underrepresented minorities in cancer clinical trials.	224
Expanding diversity in colorectal cancer studies with a focus on Hispanic and Latino participant enrollment.	222
Abemaciclib dose escalation to maintain intensity (ADE-MI).	219
Factors associated with delays in care of suspicious lung nodules at an academic medical center.	217
Mobilizing exercise recommendations for people with bone metastases: An experience-based co-design approach.	215
Impact on biomarker documentation in community oncology by optimizing clinical decision support.	214
Three-year follow-up of outcomes with KTE-X19 in patients with relapsed/refractory mantle cell lymphoma in ZUMA-2.	211
Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP).	210
Natural language processing for automated breast cancer recurrence detection and classification in computed tomography reports.	207
Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, P	204
Effects of socioeconomic status (SES) and healthcare resource (HCR) availability on survival in Black patients (pts) versus (vs) White pts with multiple myeloma (MM): A SEER Medicare analysis.	202
Breast cancer outcomes and treatment toxicity in geriatric patients compared to other patients at the Cancer Disease Hospital in Zambia.	201
Disparities in incidence and mortality of hematologic cancers in Southeast Asia: A 2020 analysis.	200
Enrollment of older adults in clinical trials for oncology indications, 2010-2020: An evaluation by the FDA.	198
NSQIP audit of enhanced recovery after surgery protocols for radical cystectomy.	198
Financial toxicity (FT), quality of life (QoL), and medication adherence patient-reported outcomes (PROs) in CLL on first-line (1L) oral oncolytics.	195
Incorporating precision oncology in everyday clinical practice: First two years of comprehensive genomic profiling (CGP) testing experience in Croatia.	194
A novel multi-cancer screening approach based on screening objectives, cancer occurrence mechanism, and cost modeling.	193
Commercial health plan spending on oncology drugs approved via the accelerated approval pathway and later withdrawn from the market.	192
A phase I/II trial of neoadjuvant pegylated arginine deiminase (ADI-PEG 20) with ifosfamide and radiotherapy in soft tissue sarcomas (STS) of the trunk or extremity.	192
Efficacy of mammography screening in women aged 40–49 years: An updated systematic review and meta-analysis.	191
Implementation of video assisted point-of-care germline genetic education and testing for patients with peri-diagnostic pancreatic cancer.	190

Phase II study of anlotinib plus durvalumab and chemotherapy as first-line treatment in extensive-stage small cell lung cancer (ES-SCLC): Efficacy and safety analysis.	189
Tislelizumab versus sorafenib in first-line treatment of unresectable hepatocellular carcinoma: Impact on health-related quality of life in RATIONALE-301 population.	189
Universal germline testing for cancer susceptibility and actionable noncancer disorders among 19,842 patients: Initial findings from the City of Hope INSPIRE study.	189
Adherence and perception of the importance of anti-COVID-19 protective measures amongst patients with cancer.	186
Effect of IL-15 on anti-tumor immune response to radio-immunotherapy through systemic immune activation.	185
PIK3CA testing and treatment patterns among patients with metastatic breast cancer in US community clinical practice.	184
Effect of war on radiotherapy in Ukraine and how to help.	184
Pelareorep driven blood TIL expansion in patients with pancreatic, breast and colon cancer.	183
The role of folate receptor-positive circulating tumor cells in the prognosis analysis of esophageal squamous cell carcinomas.	182
Predictors of long-term survival in immune checkpoint inhibitor (ICI)-associated myocarditis.	182
pionERA Breast Cancer (BC): Phase III study of first-line (1L) giredestrant vs. fulvestrant, both combined with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), in patients (pts) with estrogen recep	181
Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen recept	181
Feasibility of implementing whole genome sequencing into routine oncology care.	180
Immune checkpoint inhibitor (ICI) rechallenge after immune-related adverse events (irAE) requiring hospitalization: A single-center 10-year experience.	176
Dual-agent immunotherapy for prevention of melanoma brain metastases: A real-world analysis of 8686 patients.	175
Real-world impact of KRAS mutations on clinical outcomes in metastatic colorectal cancer treated with trifluridine-tipiracil in the USA.	173
Genomic profile in Mexican women with early-stage breast cancer using Mammaprint+Blueprint assay: A retrospective study.	168
Relationship between immune-inflammatory markers and clinical features and deepness of tumor response and prognosis of patients with PD-L1 ≥50% metastatic NSCLC receiving first-line immunotherapy.	168
Benmelstobart (TQB2450) combined with anlotinib hydrochloride capsule in the treatment of advanced, recurrent, or metastatic endometrial cancer: A multicohort, open label, multicenter, phase II clinic	168
COBRA: Assessment of safety and efficacy of 64Cu-SAR-bisPSMA in patients with biochemical recurrence of prostate cancer following definitive therapy.	165
Avelumab with axitinib in persistent or recurrent cervical cancer after platinum-based chemotherapy (ALARICE study).	164
HDAC I/IIb selective inhibitor purinostat mesylate in relapsed and refractory diffuse large B-cell lymphoma: A single agent phase IIa trial.	164
Consistent data about the predictive factors of the success of interval debulking surgery (CC0-IDS) in patients with advanced ovarian cancers in two large independent datasets.	162
VAMANA: A phase 2 study of low-dose bevacizumab plus CCNU in relapsed/recurrent glioblastoma.	161
A phase 1, multi-center, open-label, dose-escalation, and dose-expansion study of CBP-1018, a bi-ligand-drug conjugate in patients with heavily treated advanced solid tumors.	160
Informed decision-making about germline testing among Veterans with advanced prostate cancer (APC): A mixed-methods study.	158
Correlation of body mass index (BMI) with survival outcomes in patients (pts) with metastatic hormone-sensitive prostate cancer (mHSPC): Analysis of patient (pt)-level data from SWOG 1216 study.	156
Efficacy and safety of combination therapy with envafolimab and lenvatinib in patients with endometrial cancer after failure of first-line platinum-based therapy.	154
Genomic instability is enriched in localized prostate cancers from men of African ancestry.	154
Gemcitabine/paclitaxel/adriamycin (GTA) as a nephron-sparing regimen in urothelial carcinoma: The MD Anderson Cancer Center (MDACC) experience.	154
The influence of access to care on radiation therapy utilization among older women with breast cancer.	153
Effect of sodium-glucose cotransporter 2 inhibitor dapagliflozin on systemic H-FABP and monocyte-to-lymphocyte ratio in preclinical models of antracycline induced cardiotoxicity.	152
Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer.	152
Use of Oncotype vs. Breast Cancer Index (BCI) for extended endocrine therapy decisions: A single center analysis in stage IA hormone receptor positive breast cancer.	151
Upstream regulation of neurotransmitter signaling genes in metastatic colorectal cancer (mCRC) patients: Data from CALGB/SWOG 80405 trial (Alliance) and MONSTAR-SCREEN-2.	151
Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice	149
Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: A SEER-Medicare analysis.	148
Incidence of infusion related reactions of daratumumab-hyaluronidase-fihj: Pre-post intervention study of premedication omission.	147
Use of integrated multi-omics analysis to determine antitumor efficacy of donafenib in combination with FADS2 inhibition in hepatocellular carcinoma.	147
A phase 2 study to determine the pathological (path) response to neoadjuvant nivolumab (nivo) and relatlimab (rela) in stage I to III resectable Merkel cell carcinoma (Neo-MCC).	145
Clinical and translational results from REVOLUTION cohorts A (nivolumab + ipilimumab + chemotherapy) and B (hydroxychloroquine + ipilimumab + chemotherapy) in patients with previously untreated metast	145
Association of CDX2 expression with clinical, pathologic, and molecular features in MSI-H colorectal cancer.	144
Primary retroperitoneal lymph node dissection (RPLND) in seminoma stage IIA-IIC ≤3cm: Combined results of the SWENOTECA (Swedish Norwegian Testicular Cancer Group) and Cologne.	143
Randomized phase II study of platinum and etoposide (EP) versus temozolomide and capecitabine (CAPTEM) in patients (pts) with advanced G3 non-small cell gastroenteropancreatic neuroendocrine neoplasms	143
Risk of VTE in TNBC treated with neoadjuvant immunotherapy.	143
Comparison of real-world mortality data among patients with glioblastoma (GBM) and metastatic pancreatic cancer (mPC) treated in the community oncology setting.	143
Relationship of adaptive subtyping and tumour heterogeneity of treatment response to neoadjuvant therapy in hormone receptor–positive HER2-negative early breast cancer: PENELOPE-B.	139
Does the time-of-day administration of immune checkpoint inhibitors affect efficacy in patients with metastatic renal cell carcinoma? A single-center study.	139
A real-world study of anlotinib in combination with PD-L1 inhibitors plus chemotherapy as first-line therapy for extensive-stage small cell lung cancer.	138
Real world experience of bispecific fusion protein in patients with metastatic uveal melanoma: Can we deliver?	138
Oncology-specific Qualified Clinical Data Registry (QCDR) measures to advance cancer care and achieve Merit-Based Incentive Payment System (MIPS) performance.	136
Multicentric retrospective study on the treatment characteristics, efficacy and safety of eribulin in Slovenian patients with breast cancer.	136
Multiomic characterization to reveal a distinct molecular landscape in young-onset pancreatic cancer.	136
Real-world racial disparities in EGFR testing and third-generation EGFR TKI use among U.S. patients with stage IV NSCLC.	135
Dendrimer-enhanced (DEP) SN38 (DEP irinotecan) in patients (pts) with advanced solid tumors: A phase 1/2 trial.	135
Axillary pathologic response after neoadjuvant chemotherapy and surgery according to breast cancers subtypes and survival impact.	135
Neoadjuvant chemotherapy (NAC) followed by total mesorectal excision (TME) and adjuvant chemotherapy versus TME followed by adjuvant chemotherapy in very low-lying clinical (c) T3 rectal cancer (NAIR)	135
Final analysis of a prospective controlled trial of the efficacy of uracil and tegafur/leucovorin for stage II colon cancer with risk factors for recurrence using propensity score-based methods (JFMC4	134
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors.	134
A prospective study exploring the safety and efficacy of lenvatinib for patients with advanced hepatocellular carcinoma potential in current real-world practice.	134
Quality initiative (QI) to improve molecular testing in newly diagnosed (ND) stage 4 non-small cell lung cancer (NSCLC-4): An Integra Connect (IC) database study.	134
The concerning disaggregation of gender disparity and racial disparity investigation at recent ASCO annual meetings.	132
Claims-based cardiac monitoring (CM) in patients (Pts) receiving trastuzumab (TZ).	131
Predictors of electronic health record (EHR) portal registration and frequency of portal use among patients with cancer prior to engagement in the IMPACT Consortium symptom management trials.	131
A pilot intervention to improve health insurance literacy and financial toxicity among recently diagnosed adolescents and young adults with cancer.	130
Identification of super-exhausted T cells: A novel population predictive of response to immunotherapy.	129
KRAS mutation detection and cfDNA in liquid biopsy as prognostic factors in pancreatic adenocarcinoma.	128
LUNG cancer: Supportive oncology program development for patients and care partners: A qualitative study.	127
A mixed-methods study of healthcare provider perspectives on the barriers to enrollment of minority patients on cancer clinical trials.	127
Glypican-3-specific CAR-NKT cells overexpressing BATF3 mediate potent antitumor activity against hepatocellular carcinoma.	127
Preliminary clinical investigations of high-dose furmonertinib in NSCLC with EGFR Exon 20 insertions (20ins).	127
Cross-ancestry polygenic risk score for breast cancer risk assessment.	126
Significant durable response with fianlimab (anti-LAG-3) and cemiplimab (anti-PD-1) in advanced melanoma: Post adjuvant PD-1 analysis.	125
Randomized phase 2 study of DKN-01 plus FOLFIRI/FOLFOX and bevacizumab versus FOLFIRI/FOLFOX and bevacizumab as second-line treatment of advanced colorectal cancer (DeFianCe).	124
Adult BMI change over time and risk of colorectal adenoma.	124
Quality of educational YouTube videos related to pancreatic cancer: Analysis of patient-focused and NCI-designated cancer center videos.	123
Vulnerable patients with metastatic colorectal cancer in a real-world setting: A multicenter retrospective study.	122
A multicenter, case-control study of a novel multi-target fecal DNA test for colorectal cancer detection.	121
Molecular genetic sequencing of neuroendocrine tumors of the gastrointestinal tract.	120
Factors associated with weekend emergency department visits in patients with GI cancer.	120

Tumour radiomics as imaging biomarker of tumour response to chemo-radiotherapy in patients with adenocarcinoma of rectum.	120
Identifying DNA methylation signatures in high-grade serous ovarian cancer: Results vary by control tissue type.	118
Impact of prophylactic laser therapy on mucositis in patients with head and neck cancer (HNC) undergoing radiotherapy in Brazil.	117
Analyzing the effect of treatment modalities on survival in synovial sarcoma.	117
Female participation in U.S. oncology clinical trials registered on ClinicalTrials.gov from 2008 to 2020.	116
Evaluating the utility of rule OP-35 to define preventability of ED visits for oncology patients at an academic cancer center.	116
Phase 1 study of CTX-471, a novel CD137 agonist antibody, in patients with progressive disease following PD-1/PD-L1 inhibitors in metastatic or locally advanced malignancies.	116
Risk factors for ED visits and admissions during outpatient chemotherapy in head and neck cancer.	116
Treatment interruptions and discontinuations among patients with stage III unresectable non–small cell lung cancer treated with durvalumab at the Veterans Health Administration.	115
Satisfaction with and recommendations to improve telehealth visits among adolescents and young adults with cancer during the COVID-19 pandemic.	115
Race- and sex-based variation in industry research and general payments to medical oncologists in the United States.	115
Is recent FDA guidance on HRQoL clinical significance a barrier to clinician/patient treatment risk/benefit discussions: An example using EORTC scale endpoints in a randomized, phase 3 trial.	115
Non-invasive cell-free DNA monitoring for predicting the response to neoadjuvant immunotherapy in locally advanced esophageal squamous cell carcinoma.	113
Early quality of life (QOL) and symptom analysis from the DREAMseq phase III randomized control trial of combination immunotherapy versus targeted therapy in patients (pts) with BRAF-mutant met	113
CD47 expression patterns in thymic epithelial tumors.	112
Limited benefit from the addition of immunotherapy to chemotherapy in TKI-refractory EGFR-mutant lung adenocarcinoma.	111
Characterization of patients with metastatic melanoma that relapses following complete metabolic response from anti–PD-1 therapy.	111
Financial distress, health literacy, numeracy, and treatment receipt by race/ethnicity amongst breast cancer survivors.	111
Genomic landscape and clonal evolution between adenocarcinoma and squamous components in adenosquamous carcinoma of the pancreas.	111
Systematic assessment of online health information related to drug therapy for non-small cell lung cancer.	110
Are we providing adequate information? patient-specific clinical trial information at NCI-designated cancer center websites.	109
Utilization and financial coverage of blood based next generation sequencing for solid tumors: A study from Augusta-Georgia.	109
Variation in survival rates among patients with angiosarcoma based on demographic and socioeconomic factors in academic versus non-academic settings: An NCDB analysis.	109
Multi-modal single-cell profiling of sarcomas from archival tissue reveals mechanisms of resistance to immune checkpoint inhibitors.	108
Obesity diabetes and dyslipidemia as determinants of immune checkpoint inhibitors response in non-small cell lung cancer.	108
Awareness of the link between HPV, cervical cancer, and HPV vaccination: An online survey among Polish women.	108
Randomized controlled trial (RCT) of symptom screening with targeted early palliative care (STEP) versus usual care in patients with advanced cancer.	107
Circulating nucleosomes to identify non-smoker subjects at risk of lung cancer and triage them for low-dose CT scan.	107
Patients with cancer symptom and physical function reporting by caregivers as predictors of adverse clinical outcomes.	107
Polymorphism rs4673 and plasma paraoxonase 1 level for prediction and early diagnosis of anthracycline-mediated cardiotoxicity in patients with breast cancer.	107
Effectiveness of immunotherapy versus BRAF/MEK inhibitors in treatment-naïve BRAF-mutant advanced melanoma: A single institution retrospective analysis.	106
Uncommon EGFR mutations conducted with osimertinib in patients with NSCLC (UNICORN): A phase 2 study.	106
Risk of second cancers in long term survivors of neuroendocrine tumors of the large intestine.	106
Trends in the incidence of early-onset invasive colorectal cancer between 1990 and 2018, stratified by race/ethnicity, gender, and anatomic sub-sites among Pennsylvania residents.	106
Association of enhanced epithelial-mesenchymal transition signature with tumor microenvironment, angiogenesis, and survival in gastric cancer.	105
The prognostic role of sarcopenia and albumin in locally advanced renal cell carcinoma with IVC tumor thrombus.	105
Correlation between PD-L1 high-expression and EGFR variants in non-small cell lung cancer.	105
Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy (SBRT) for patients with locally advanced pancreatic cancer and borderline pancreatic inoperabl	104
Beyond gemtuzumab ozogamicin: A systematic review of antibody therapies for acute myeloid leukemia.	104
A prospective exploratory clinical study of penpulimab plus anlotinib as first-line treatment for locally advanced or metastatic urothelial carcinoma.	103
Development of a remote monitoring program for melanoma/skin oncology patients at Princess Margaret Cancer Centre.	103
The impact of virtual live education on the competence and knowledge of gynecologists caring for ovarian cancer patients.	103
Scenery of multilocus inherited neoplasia alleles syndrome (MINAS) in a single Brazilian institution.	103
Mutational profiles of sporadic synchronous colorectal cancer.	102
Clinical utility of urine DNA for noninvasive detection and minimal residual disease monitoring in urothelial carcinoma.	102
A real-world study of prognostic factors and risk-stratification model from Taiwanese patients with recurrent or metastatic head and neck squamous cell carcinoma treated with cetuximab containing regi	101
Pan-Cancer analysis of the mutation frequency of genes in DDR pathway in Chinese population.	101
Evaluation of serum vascular endothelial growth factor as a biomarker in Erdheim-Chester disease.	100
A cross sectional study on female sexual function following pelvic radiotherapy.	100
Associations between genomic instability score (GIS), molecular characterization, and clinical outcomes in high grade serous ovarian cancers (HGSOC).	100
Hereditary cancer screening at an urban safety net hospital.	100
Low baseline vitamin D levels correlate with adverse pathological features and clinical outcomes among patients with breast cancer.	98
Impact of broadening trial eligibility criteria on the inclusion of patients with brain metastases in cancer clinical trials.	97
Participation in cancer research in BNSSG, England: A Health Equity Audit 2021.	97
Improving goal concordant care clinician workshops: Do patients benefit?	97
Efficacy and surgical safety of sequential surgical resection after neoadjuvant chemoimmunotherapy for unresectable stage III NSCLC.	96
Filling the gap in competency-based training for medical oncology with supervised online patient counseling: A qualitative study.	96
Pegylated liposomal doxorubicin combined with ifosfamide for advanced soft tissue sarcomas: A phase I dose-escalation study.	95
Prevalence of pathogenic variants in non-BRCA genes and their impact on clinical practice in Argentina.	95
Rates of potentially actionable germline variants in homologous recombination repair genes in a large international cohort outside of the United States.	95
Real-time evidence synthesis for first line (1L) treatment of metastatic renal cell carcinoma (mRCC): A living, interactive systematic review and Bayesian network meta-analysis.	95
Understanding the late immune checkpoint inhibitor (ICI) symptom experience using an electronic patient reported outcomes (ePRO) app-based platform: The immunowave study.	95
Updated health-related quality of life of patients with TRK-fusion cancer treated with larotrectinib in clinical trials.	95
Therapeutic interchange: The cornerstone of cost effectiveness in the Oncology Care Model performance for the U.S. Oncology Network.	94
Influence of widely targeted quantitative lipidomics on plasma lipid predictors and pathway dysregulation for nasopharyngeal carcinoma.	93
Cancer risk assessment in patients with persistent pulmonary nodules and its correlation with cancer-free survival.	93
Concurrent durvalumab plus chemoradiation therapy followed by durvalumab in Chinese patients with unresectable stage III non-small cell lung cancer: CRUISER study.	93
Safety of locally administered large surface area microparticle paclitaxel and docetaxel in combination with standard of care cancer therapies.	93
Real-world treatment outcomes in patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who were treated with first-line single-agent ibrutinib vs. chemoimmunotherapy.	93
Lack of organization to access cancer treatment in southeast Brazil: Urgent need to change.	92
Phase II trial of combination pembrolizumab, olaparib, and temozolomide for patients with recurrent glioma.	92
Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer.	92
Beyond the binary: Analysis of esophageal cancer hospitalizations in the transgender population, a national inpatient sample study.	92
Knowledge and use of different breast cancer screening tools among primary care physicians: A cross-sectional study.	92
Colon adjuvant chemotherapy based on evaluation of residual disease (CIRCULATE-US): NRG-GI008.	92
Prognostic value of month 1 bone marrow and PET MRD status in CAR-T therapy for myeloma.	92
The association of progesterone receptor and abnormal p53 expression in endometrioid endometrial cancer.	92
Influence of chromatin remodeling molecule ARID1A on metastatic heterogeneity in triple negative breast cancer: Binding of YAP.	91
A randomized study of consolidation chemoradiation (CTRT) vs observation after first-line chemotherapy (CT) in advanced gall bladder cancers (GBC): RACE-GB Study.	91
A phase II study of afatinib in combination with pemetrexed and carboplatin in patients with EGFR mutation positive non-squamous, advanced non–small-cell lung cancer (NSCLC) refractory to first-line o	91
A deep learning model for the prediction of microsatellite instability and pathogenic POLE mutations in colorectal cancer using histopathologic images.	91
Comparison of real-world outcomes over time in a large population-based cohort of patients with metastatic breast cancer.	90
Integrated clinico-genomic characterization of pancreatic ductal adenocarcinoma in an Asian population.	90
Representativeness of patients with lung cancer in an integrated health care delivery system.	89
Burnout in oncology nurses.	88
The molecular signature of gain-of-function (GOF) vs. non-GOF classification TP53 mutations in colorectal cancer.	88
Reevaluating the role of adjuvant chemotherapy in early-stage, resectable NSCLC with high-risk clinical and pathologic features.	88
Outcomes of renal function and efficacy in patients with muscle invasive bladder cancer treated by tislelizumab-based immunochemotherapy.	87
Attachment avoidance and anxiety impacting dyadic coping and communication in patients with metastatic sarcoma and their family caregivers.	86
Redefining early-onset cancer and risk of hereditary cancer predisposition.	86
Single cell multiomic profiling of high-grade serous carcinoma.	86
Incidence of solid malignancies (SM) among patients with Waldenström macroglobulinemia (WM): Analysis of the SEER database (2000-2019).	86
Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases.	86
Impact of economic inequality on Kaposi sarcoma of the lung: A retrospective cohort.	85
Comparison of diversity across real-world evidence, randomized clinical trial, and Surveillance, Epidemiology, and End Results (SEER) data in patients with metastatic breast cancer.	85